Intercontinental Exchange, Inc., together with its subsidiaries, engages in the provision of market infrastructure, data services, and technology solutions for financial institutions, corporations, and government entities in the United States, the United Kingdom, the European Union, Singapore, India, Abu Dhabi, Israel, and Canada. It operates through three segments: Exchanges, Fixed Income and Data Services, and Mortgage Technology. The company operates regulated marketplaces for listing, trading, and clearing an array of derivatives contracts and financial securities, such as commodities, interest rates, foreign exchange, and equities, as well as corporate and exchange-traded funds; and trading venues, including regulated exchanges and clearing houses. It also offers energy, agricultural and metals, and financial futures and options; and cash equities and equity options, and over-the-counter and other markets, as well as listings and data and connectivity services. In addition, the company provides fixed income data and analytic, fixed income execution, CDS clearing, and other multi-asset class data and network services. Further, it offers proprietary and comprehensive mortgage origination platform, which serves residential mortgage loans; closing solutions that provides customers connectivity to the mortgage supply chain and facilitates the secure exchange of information; data and analytics services; and Data as a Service for lenders to access data and origination information. Intercontinental Exchange, Inc. was founded in 2000 and is headquartered in Atlanta, Georgia.

Intercontinental Exchange Inc.

CME Group Inc. CME is expected to register an improvement in its top and bottom lines when it reports second-quarter 2025 results on July 23, before the opening bell.
The Zacks Consensus Estimate for CME’s second-quarter revenues is pegged at $1.68 billion, indicating 9.4% growth from the year-ago reported figure.
The consensus estimate for earnings is pegged at $2.90 per share. The Zacks Consensus Estimate for CME’s second-quarter earnings has moved down 5.71.3% in the past 30 days. The estimate suggests a year-over-year increase of 13.2%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
What the Zacks Model Says
Our proven model predicts an earnings beat for CME Group this time. This is because the stock has the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), which increases the chances of an earnings beat.
Earnings ESP: CME Group has an Earnings ESP of +0.93%. This is because the Most Accurate Estimate of $2.93 is pegged higher than the Zacks Consensus Estimate of $2.90. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
CME Group Inc. Price and EPS Surprise
Zacks Rank: CME Group currently carries a Zacks Rank of 3.
Factors Likely to Shape Q2 Results
CME Group’s second-quarter performance is likely to have benefited from a diverse product portfolio, increased volatility and a strong market position.
Revenues are likely to have benefited from an increase in market data and information services, clearing, transaction fees and other revenues.
Higher trading volumes across asset classes are likely to have driven clearing and transaction fees. We expect clearing and transaction fees to be $1.3 billion, indicating a 7.7% increase from the year-ago reported figure. The Zacks Consensus Estimate for second-quarter clearing and transaction fees is pegged at $1.4 billion, indicating a rise of 9.5% from the year-ago reported figure.
CME reported a record quarterly average daily volume of 30.2 million contracts in the second quarter, up 16% year over year. This was driven by record quarterly volume in Interest Rate, Agricultural‌ and Metals products. International ADV reached a record 9.2 million contracts, up 18% year on year.
Market data and information services revenues are likely to have gained from price increases for certain products, a rise in device counts, higher custody fees, as well as improvements in co-location and other connectivity fees. We expect the figure to be $196.7 million, indicating a 12.4% increase from the year-ago reported figure. The Zacks Consensus Estimate for second-quarter market data and information services revenues is pegged at $195 million, indicating an increase of 11.4% from the year-ago reported figure.
Expenses are likely to have increased in the to-be-reported quarter due to higher compensation and benefits and technology expenses. We anticipate expenses to be $513.9 million in the to-be-reported quarter, indicating an 8.4% increase from the year-ago reported figure.
Other Stocks to Consider
Here are three finance stocks you may want to consider, as our model shows that these also have the right combination of elements to post an earnings beat.
Nasdaq, Inc. NDAQ has an Earnings ESP of +0.47% and carries a Zacks Rank #2 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at 80 cents, indicating a year-over-year increase of 15.9 %. You can see the complete list of today’s Zacks #1 Rank stocks here.
NDAQ’s beat estimates in each of the last four reported quarters.
Intercontinental Exchange Inc. ICE has an Earnings ESP of +0.57% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at $1.76, indicating a year-over-year increase of 15.7%.
ICE’s earnings beat estimates in three of the last four reported quarters while meeting the same in one.
MarketAxess Holdings Inc. MKTX has an Earnings ESP of +0.95% and carries a Zacks Rank of 3 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at $1.94, implying an increase of 12.7% from the year-ago reported figure.
MKTX’s beat estimates in each of the last four reported quarters.
One Big Gain, Every Trading Day
To help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.
Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.
Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is a Beat in the Cards for CME Group This Earnings Season?

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? IntercontinentalExchange (ICE), which belongs to the Zacks Securities and Exchanges industry, could be a great candidate to consider.
This owner of the New York Stock Exchange and other stock markets has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 1.59%.
For the most recent quarter, ICE was expected to post earnings of $1.72 per share, but it reported $1.7 per share instead, representing a surprise of 1.18%. For the previous quarter, the consensus estimate was $1.49 per share, while it actually produced $1.52 per share, a surprise of 2.01%.
Price and EPS Surprise
Thanks in part to this history, there has been a favorable change in earnings estimates for ICE lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
ICE currently has an Earnings ESP of +0.57%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on July 31, 2025.
With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Will ICE (ICE) Beat Estimates Again in Its Next Earnings Report?

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Mega Cap Value ETF (Symbol: MGV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $144.24 per unit.
With MGV trading at a recent price near $131.35 per unit, that means that analysts see 9.81% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of MGV's underlying holdings with notable upside to their analyst target prices are Berkshire Hathaway Inc (Symbol: BRK.A), Intercontinental Exchange Inc (Symbol: ICE), and Exxon Mobil Corp (Symbol: XOM). Although BRK.A has traded at a recent price of $707681.00/share, the average analyst target is 10.65% higher at $783033.00/share. Similarly, ICE has 10.52% upside from the recent share price of $180.80 if the average analyst target price of $199.82/share is reached, and analysts on average are expecting XOM to reach a target price of $123.39/share, which is 9.94% above the recent price of $112.23. Below is a twelve month price history chart comparing the stock performance of BRK.A, ICE, and XOM:
Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
Vanguard Mega Cap Value ETF
MGV
$131.35
$144.24
9.81%
Berkshire Hathaway Inc
BRK.A
$707681.00
$783033.00
10.65%
Intercontinental Exchange Inc
ICE
$180.80
$199.82
10.52%
Exxon Mobil Corp
XOM
$112.23
$123.39
9.94%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Add Up The Parts: MGV Could Be Worth $144

Last Friday, the three most widely followed benchmark indexes closed a losing week. The Dow Jones Industrial Average, the S&P 500 and the Nasdaq Composite lost 1%, 0.3% and 0.1%, respectively.
The pullback stemmed from renewed U.S. tariff threats. Higher levies on Canada, the European Union and other countries have unnerved markets and raised concerns about economic growth and inflation. Despite this, many investors shrugged off the headlines, focusing on robust earnings from airlines and consumer stocks and a still-resilient economy.
Yet, caution prevailed as markets await key CPI data due this week. Investors need to assess more reports coming in from the second-quarter earnings season to gauge how tariffs may erode corporate profits.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Mogo and ATI Surge Following Zacks Rank Upgrade
Shares of Mogo Inc. MOGO have gained 81.8% (versus the S&P 500’s 11.1% increase) since it was upgraded to a Zacks Rank #2 (Buy) on May 8.
Another stock, ATI Inc. ATI, which was also upgraded to a Zacks Rank #2 on May 6, has returned 32.6% (versus the S&P 500’s 10.7% increase) since then.
A hypothetical portfolio of Zacks Rank # 1 (Strong Buy) stocks returned +6.51% in May 2025, which compares to +4.47% for the S&P 500 index and +4.12% for the equal-weight version of the index. This follows the Zacks Rank # 1 stocks’ +17.96% return in April vs. +15.04% for the S&P 500 index.
This hypothetical portfolio has returned -2.59% in 2025 (through June 2nd) vs. -1.12% for the S&P 500 index and -4.41% for the equal-weight version of the index.
This portfolio returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 12 percentage points since 1988 (through June 2nd, 2025, the Zacks # 1 Rank stocks generated an annualized average return of +23.5% vs. +11% for the S&P 500 index).
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades Amarin and European Wax Center
Shares of Amarin Corporation plc AMRN and European Wax Center, Inc. EWCZ have surged 62.6% and 49.9% (versus the S&P 500’s 10.5% rise), respectively, since their Zacks Recommendation was upgraded to Outperform on May 12.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Intellia, Lam Research Shoot Up
Shares of Intellia Therapeutics NTLA, which belongs to the Zacks Focus List, have gained 53.8% over the past 12 weeks. The stock was added to the Focus List on March 7, 2023. Another Focus-List holding, Lam Research Corporation LRCX, which was added to the portfolio on December 5, 2016, has returned 49.9% over the past 12 weeks. The S&P 500 has advanced 15.7% over this period.
The 50-stock Focus List portfolio returned 8.84% in 2025 (through June 30th, 2025) vs. +6.21% for the S&P 500 index and +4.82% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
The portfolio leads the broader market over the preceding one, three, five and ‘since 2004’ periods. These annualized return comparisons are: +22.27% for the Focus List vs. +15.18% for the index over the one-year period, +22.61% vs. +19.71% over the 3-year period, +17.79% vs. +16.64% over the 5-year period, and +11.85% vs. +11.44% since 2004.
Since 2004, the Focus List portfolio has produced an annualized return of +11.60% (through the end of May 2025). This compares to a +10.22% annualized return for the S&P 500 index and +9.41% for the equal-weight version of the index in the same time period.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Intuit & Mettler-Toledo Make Significant Gains
Intuit Inc. INTU, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 26% over the past 12 weeks. Mettler-Toledo International Inc. MTD has followed Intuit with 13% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned +3.20% in the first quarter of 2025 vs. the S&P 500 index’s -4.30% decline (SPY ETF).
For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks 3M and Intercontinental Exchange Outperform Peers
3M Company MMM, which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 14.6% over the past 12 weeks. Another ECDP stock, Intercontinental Exchange, Inc. ICE, has climbed 13% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned +5.74% in 2025 Q1 vs. the S&P 500 index’s -2.41% pullback and the Dividend Aristocrats ETF’s (NOBL) +3.11% return.
For the full-year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stock Stride Delivers Solid Returns
Stride, Inc. LRN, from the Zacks Top 10 Stocks for 2025, has jumped 29.4% year to date compared with the S&P 500 Index’s 6.4% increase.
The Top 10 portfolio returned +11.8% this year (through the end of June 2025) vs. +6.2% for the S&P 500 index and +4.8% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +2,246.8% through the end of June 2025 vs. +502.3% for the S&P 500 index and +373.4% for the equal-weight version of the index. The portfolio has produced an average return of +26.3% in the period 2012 through June 30, 2025, vs. +14.3% for the S&P 500 index and +12.2% for the equal-weight version of the index.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

Thursday, June 26, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), NVIDIA Corp. (NVDA) and Bank of America Corp. (BAC), as well as two micro-cap stocks BK Technologies Corp. (BKTI) and NeurAxis, Inc. (NRXS). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Big Changes in Economic Data, Pre-Markets Hold Gains
Today's Featured Research Reports
Microsoft’s shares have outperformed the Zacks Computer - Software industry over the year-to-date period (+17.3% vs. +13.9%). The company capitalizes on AI business momentum and Copilot adoption alongside accelerating Azure cloud infrastructure expansion. Strong Office 365 Commercial demand has been propelling Productivity and Business Processes revenue growth. ARPU increases through E5 and M365 Copilot uptake across key segments.
Intelligent Cloud revenues advance through Azure AI development and AI Copilot business growth. Strategic execution has been enhancing non-AI services through enterprise customer growth and operational scale improvements. Xbox content and services benefit from robust performance across third-party and first-party content offerings.
The Zacks analyst expects that fiscal 2025 net sales will increase 13.7% compared to fiscal 2024. However, elevated operating expenses and Azure investments amid intensifying cloud competition remain concerns for the stakeholders.
(You can read the full research report on Microsoft here >>>)
Shares of NVIDIA have outperformed the Zacks Semiconductor - General industry over the past year (+24.5% vs. +20.8%). The company is benefiting from the strong growth of artificial intelligence (AI), high-performance and accelerated computing. The growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA’s Hopper and Blackwell architectures is aiding data center revenues.
Continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. Collaborations with over 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicles space.
The Zacks analyst expects NVIDIA’s revenues to witness a CAGR of 28.95% through fiscal 2026-2028. However, a limited supply of Blackwell and Ada GPUs could hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins.
(You can read the full research report on NVIDIA here >>>)
Bank of America’s shares have gained +22.3% over the past year against the Zacks Financial - Investment Bank industry’s gain of +40.9%. While the company’s high funding costs are still a woe, net interest income (NII) will be positively impacted by relatively higher rates. The Zacks analyst expect NII to record a CAGR of 5.3% by 2027. Plans to open financial centers in new and existing markets and improve digital capabilities will aid the top line. We project total revenues to grow 5.8% in 2025.
Nevertheless, the volatile nature of the trading business is a concern. Despite an impressive trading performance since 2022, it is expected to normalize going forward, thus hurting fee income growth. We project non-interest income to rise only 4.5% in 2025.
Also, steady investments in the franchise will likely keep operating expenses elevated, thus hurting profitability. We expect total non-interest expenses to rise 3% this year. While high funding costs are still a woe,
(You can read the full research report on Bank of America here >>>)
Shares of BK Technologies have outperformed the Zacks Wireless Equipment industry over the year-to-date period (+58.2% vs. +7.8%). This microcap company with market capitalization of $199.92 million has achieved seven consecutive profitable quarters, driven by margin expansion and operational efficiency. First-quarter 2025 GAAP EPS rose to $0.55 and adjusted EPS to $0.68, supported by a product mix shift to higher-margin BKR 9000 radios and an asset-light model.
Gross margin was 47%, and the 2025 guidance targets exceed $2.80 in adjusted EPS. The BKR 9000 is expanding across public safety verticals and the BK ONE SaaS platform adds high-margin, recurring revenue potential. A growing hardware-software ecosystem aims to boost the addressable market tenfold by 2027.
Strong liquidity funds growth, but risks include federal revenue reliance, execution risk in SaaS adoption, margin pressure from tariffs and delays in mobile product launches. BKTI’s valuation assumes continued execution despite infrastructure and liquidity limitations.
(You can read the full research report on BK Technologies here >>>)
NeurAxis’ shares have gained +10.2% over the year-to-date period against the Zacks Medical Info Systems industry’s gain of +18%. This microcap company with market capitalization of $17.61 million targets a large, underserved $8 billion pediatric gut-brain disorder market with its FDA-cleared IB-Stim therapy for functional abdominal pain and dyspepsia, conditions affecting more than 600,000 U.S. children.
Backed by 16 peer-reviewed studies and NASPGHAN guidelines, IB-Stim’s market potential doubled with its May 2025 label expansion. Covered lives grew from 4 million to 53 million, and a permanent CPT code will boost physician adoption and margins.
The RED device clearance opens a $2 billion adult diagnostic market. Risks include high cash burn, slow CPT implementation and reliance on discounted sales. Yet, strong IP and a first-mover edge in a $22 billion market support long-term growth. The valuation suggests that investors are pricing in strong growth potential but remain cautious due to execution and reimbursement risks.
(You can read the full research report on NeurAxis here >>>)
Other noteworthy reports we are featuring today include The Coca-Cola Co. (KO), Intercontinental Exchange, Inc. (ICE) and HEICO Corp. (HEI).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
Coca-Cola's (KO) All-Weather Strategy to Boost the Top Line
Per the Zacks analyst, Coca-Cola's all-weather strategy that blends marketing, innovation, and revenue growth management, supports its total beverage vision. This is expected to drive revenues in 2025
Intercontinental (ICE) Banks on Acquisitions Amid High Costs
Per the Zacks analyst, Intercontinental Exchange is set to grow on a number of acquisitions and cost synergies, which in turn, position it well for growth. However, rising expenses weigh on margins.
Hess (HES) to Benefit From Bakken Shale & Guyana Operations
Hess' steady growth in offshore Guyana operations and rising drilling activity in the Bakken are expected to boost production. However, rising operational costs concern the Zacks analyst.
Inside Sales Surge Fuels Casey's (CASY) Q4 Momentum
Per the Zacks analyst, Casey's posted solid Q4 results with a 12.4% rise in inside sales, driven by strong demand for prepared foods, bakery items, and beverages across its store network.
Continuous Digitalization Aids SoFi (SOFI), Liquidity Low
Per the Zacks Analyst, SoFi is poised for growth due to continuous digitalization in the financial sector, given its focus on online banking and product offerings. Low liquidity is concerning.
Expanding Vehicle Portfolio Aids NIO Amid Rising Expenses
Per the Zacks analyst, expanding vehicle lineup is aiding NIO's delivery growth. However, rising SG&A expenses are likely to weigh on the company's margins.
Ionis' (IONS) Progress With Wholly-Owned Drugs Encouraging
The Zacks Analyst is encouraged by Ionis' progress with its wholly owned pipeline. Its collaboration with big pharma provides it with funds to invest in their development.
New Upgrades
Strategic Acquisitions and Strong Solvency Position Aid HEICO Corporat
Per the Zacks analyst, HEICO Corporation is likely to benefit from its disciplined strategic acquisitions. It also holds a strong solvency position.
Robust Public Spending Trends Benefit Fluor's (FLR) Growth
Per the Zacks analyst, Fluor's prospects are gaining on the robust public infrastructure demand trends, reflecting higher activity on large projects and incremental backlog growth.
NETGEAR (NTGR) Rides on NFB Momentum & Recurring Revenues
Per the Zacks analyst, NETGEAR for Business ("NFB") revenues grows on strong ProAV switch sales, with 559,000 recurring subscribers. Rising recurring revenues boost stability and cash flow.
New Downgrades
Higher Costs & Weaker Demand Ail Eastman Chemical (EMN)
Per the Zacks analyst, higher input and energy costs will weigh on the company's margins. It also faces headwinds from softness in automotive, building & construction and consumer durables markets.
Growing Macroeconomic Woes, FX Impacts Ail Medtronic (MDT)
The Zacks analyst is concerned with Medtronic facing supply-related challenges in several markets, with tariffs adding to the pressure. Further, currency headwinds continue to weigh on performance.
Mounting Expenses Irk Integra (IART) Amid Tough Competition
The Zacks analyst is worried about Integra's escalating expenses that are putting pressure on the company's bottom line. Also, industry wide intense competition could adversely affect its performance.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Stock Reports for Microsoft, NVIDIA & Bank of America

Last Friday, the three most widely followed benchmark indexes closed a mixed week. The Dow Jones Industrial Average remained virtually unchanged. The S&P 500 declined 0.2% and the Nasdaq Composite went up by 0.2%.
The week’s trading was heavily influenced by easing geopolitical tensions in the Middle East and shifting expectations around interest rates. Hopes of de-escalation between Israel and Iran helped lift equities after a midweek dip, while oil prices dropped from recent highs, signaling reduced immediate supply risks.
Meanwhile, the Federal Reserve held rates steady but hinted at two possible cuts later this year, providing some boost to investor sentiment. Global central bank actions added to the mixed tone, with surprises from the Swiss National Bank and Brazil’s broader risk appetite. Markets now await further clarity from the upcoming congressional testimony by Fed Chair Jerome Powell.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Avino Silver & Gold Mines and WISeKey Surge Following Zacks Rank Upgrade
Shares of Avino Silver & Gold Mines Ltd. ASM have gained 78.1% (versus the S&P 500’s 15.6% increase) since it was upgraded to a Zacks Rank #1 (Strong Buy) on April 22.
Another stock, WISeKey International Holding AG WKEY, which was upgraded to a Zacks Rank #2 (Buy) on April 24, has returned 61.3% (versus the S&P 500’s 10.9% increase) since then.
A hypothetical portfolio of Zacks Rank # 1 (Strong Buy) stocks returned +6.51% in May 2025, which compares to +4.47% for the S&P 500 index and +4.12% for the equal-weight version of the index. This follows the Zacks Rank # 1 stocks’ +17.96% return in April vs. +15.04% for the S&P 500 index.
This hypothetical portfolio has returned -2.59% in 2025 (through June 2nd) vs. -1.12% for the S&P 500 index and -4.41% for the equal-weight version of the index.
This portfolio returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 12 percentage points since 1988 (through June 2nd, 2025, the Zacks # 1 Rank stocks generated an annualized average return of +23.5% vs. +11% for the S&P 500 index).
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades Silence Therapeutics and Oddity Tech
Shares of Silence Therapeutics plc SLN and Oddity Tech Ltd. ODD have surged 77.1% (versus the S&P 500’s 7.9% rise) and 12.3% (versus the S&P 500’s 6.3% rise), since their Zacks Recommendation was upgraded to Outperform on April 28 and May 2, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Palantir, Axon Shoot Up
Shares of Palantir Technologies Inc. PLTR, which belongs to the Zacks Focus List, have gained 51% over the past 12 weeks. The stock was added to the Focus List on March 26, 2024. Another Focus-List holding, Axon Enterprise, Inc. AXON, which was added to the portfolio on June 3, 2020, has returned 38.8% over the past 12 weeks. The S&P 500 has advanced 5.3% over this period.
The 50-stock Focus List portfolio returned +6.33% in April 2025 vs. +6.29% for the S&P 500 index and -5.01% for the equal-weight version of the index.
Year to date, the Focus List portfolio has returned +2.90% (through May 31st, 2025) vs. +1.07% for the S&P 500 index and -7.74% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
The portfolio leads the broader market over the preceding one, three, five and 10-year periods. These annualized return comparisons are: +15.39% for the Focus List vs. +13.54% for the index over the one-year period, +16.56% vs. +14.41% over the 3-year period, +17.01% vs. +15.94% over the 5-year period, and +13.12% vs. +12.86% over the 10-year period.
Since 2004, the Focus List portfolio has produced an annualized return of +11.60% (through the end of May 2025). This compares to a +10.22% annualized return for the S&P 500 index and +9.41% for the equal-weight version of the index in the same time period.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Oracle & Walmart Make Significant Gains
Oracle Corporation ORCL, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 34.8% over the past 12 weeks. Walmart Inc. WMT has followed Oracle with 11.8% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned +3.20% in the first quarter of 2025 vs. the S&P 500 index’s -4.30% decline (SPY ETF).
For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks Automatic Data and Intercontinental Exchange Outperform Peers
Automatic Data Processing, Inc. ADP, which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 3.7% over the past 12 weeks. Another ECDP stock, Intercontinental Exchange, Inc. ICE, has climbed 2.3% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned +5.74% in 2025 Q1 vs. the S&P 500 index’s -2.41% pullback and the Dividend Aristocrats ETF’s (NOBL) +3.11% return.
For the full-year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stock Credo Technology Delivers Solid Returns
Credo Technology Group Holding Ltd CRDO, from the Zacks Top 10 Stocks for 2025, has jumped 27.2% year to date compared with the S&P 500 Index’s 1.4% increase.
The Top 10 portfolio returned -7.88% this year (through the end of April 2025) vs. -4.92% for the S&P 500 index and -2.88% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +1832.3% through the end of April 2025 vs. +434.2% for the S&P 500 index and +338.6% for the equal-weight version of the index. The portfolio has produced an average return of +24.3% in the period 2012 through April 30, 2025, vs. +11.6% for the S&P 500 index and +9.58% for the equal-weight version of the index.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus

(RTTNews) - Intercontinental Exchange, Inc. (ICE), parent of the New York Stock Exchange, announced it will dual-list on the NYSE Texas from June 17, 2025.
The move supports Texas's growing pro-business environment and follows the recent launch of NYSE Texas, the first securities exchange operating in the state.
ICE Chair and CEO Jeffrey C. Sprecher highlighted the company's commitment to capital markets innovation and welcomed the opportunity to join the NYSE Texas community. ICE will continue to maintain its primary listing on the NYSE.
ICE is currently trading at $180.1 or 0.93% higher on the NYSE.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Intercontinental Exchange To Dual-List On NYSE Texas Starting June 17, 2025

Below is Validea's guru fundamental report for INTERCONTINENTAL EXCHANGE INC (ICE). Of the 22 guru strategies we follow, ICE rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout yields.
INTERCONTINENTAL EXCHANGE INC (ICE) is a large-cap growth stock in the Investment Services industry. The rating using this strategy is 75% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
MARKET CAP:
PASS
STANDARD DEVIATION:
PASS
TWELVE MINUS ONE MOMENTUM:
NEUTRAL
NET PAYOUT YIELD:
NEUTRAL
FINAL RANK:
FAIL
Detailed Analysis of INTERCONTINENTAL EXCHANGE INC
ICE Guru Analysis
ICE Fundamental Analysis
More Information on Pim van Vliet
Pim van Vliet Portfolio
About Pim van Vliet: In investing, you typically need to take more risk to get more return. There is one major exception to this in the factor investing world, though. Low volatility stocks have been proven to outperform their high volatility counterparts, and do so with less risk. Pim van Vliet is the head of Conservative Equities at Robeco Asset Management. His research into conservative factor investing led to the creation of this strategy and the publication of the book "High Returns From Low Risk: A Remarkable Stock Market Paradox". Van Vliet holds a PhD in Financial and Business Economics from Erasmus University Rotterdam.
Additional Research Links
Top Financial Stocks
Dividend Aristocrats 2025
Wide Moat Stocks
Recession Proof Stocks
Cheapest Value Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ICE Quantitative Stock Analysis

Shares of Cboe Global Markets, Inc. CBOE have gained 35.1% in the past year, outperforming the industry's growth of 27.9%, the Finance sector’s return of 20.7% and the Zacks S&P 500 composite’s appreciation of 11.2%.
Cboe Global has outperformed its peers, including Intercontinental Exchange Inc. ICE, S&P Global Inc. SPGI and OTC Markets Group Inc. OTCM. Shares of ICE, SPGI and OTCM have gained 32%,16.4% and 2.8%, respectively, in the past year.
CBOE vs Industry, Sector & S&P 500 in 1 Year
Image Source: Zacks Investment Research
With a market capitalization of $23.69 billion, the average volume of shares traded in the last three months was 0.9 million. CBOE has a solid track record of beating earnings estimates in three of the last four quarters, while missing in one, the average being 1.95%.
CBOE Shares are Undervalued
Cboe Global shares are trading at a discount to the Zacks Securities and Exchange industry. Its forward price-to-earnings of 23.19X is lower than the industry average of 25.89X.
Image Source: Zacks Investment Research
CBOE Trading Above 50-Day and 200-Day Moving Averages
Shares of Cboe Global closed at $226.30 on Thursday and are trading above the 50-day and 200-day simple moving averages (SMA) of $221.41 and $210.75, respectively, indicating solid upward momentum. SMA is a widely used technical analysis tool to predict future price trends by analyzing historical price data.
CBOE Price Movement vs. 50- Day, 200-Day Moving Average
Image Source: Zacks Investment Research
CBOE’s Growth Projection Encourages
The Zacks Consensus Estimate for Cboe Global’s 2025 earnings per share indicates a year-over-year increase of 10.3%. The consensus estimate for revenues is pegged at $2.25 billion, implying a year-over-year improvement of 8.4%.
The consensus estimate for 2026 earnings per share and revenues indicates an increase of 5.9% and 4.7%, respectively, from the corresponding 2025 estimates.
The long-term earnings growth is expected to be 10.5%, better than the industry average of 10.1%. Earnings have grown 11.4% in the past five years, better than the industry average of 9.6%.
Optimist Analyst Sentiment on CBOE
One of the 11 analysts covering the stock has raised estimates for 2025, and one analyst has raised the same for 2026 over the past 30 days. Thus, the Zacks Consensus Estimate for 2025 and 2026 earnings has moved up 0.5% and 0.2%, respectively, in the past 30 days.
Image Source: Zacks Investment Research
Average Target Price for CBOE Suggests Upside
Based on short-term price targets offered by 15 analysts, the Zacks average price target is $225.00 per share. The average suggests a potential 0.9% upside from the last closing price.
Image Source: Zacks Investment Research
Factors Impacting CBOE
Cboe Global’s organic strength lies in a diversified business mix that ensures uninterrupted revenue generation and recurring non-transaction revenues.
CBOE remains on track to grow its recurring non-transaction revenues. Increases in access and capacity fees and proprietary market data fees are likely to boost Data Vantage’s net revenues. Data Vantage is well-positioned to perform well in 2025. CBOE estimates Data Vantage organic net revenue growth to be in the mid to high single-digit range in 2025.
The company achieved a greater global breadth of services and products, as well as new distribution channels, apart from generating revenues and cost synergies through strategic buyouts.
Banking on operational expertise, the company has been strengthening its balance sheet by improving its cash position and lowering its debt balance. Its leverage ratio, as well as the times interest earned, compares favorably with the industry average.
CBOE’s strategic investments are well supported by solid capital management. However, higher expenses remain a major concern.
Cboe Global has been facing intense competition due to increased market consolidation that tends to reduce market share, and this includes both product and price competition.
The company’s investment in European, Canadian and Asia Pacific operations remains exposed to volatility in currency exchange rates through translation of net assets or equity to U.S. dollars. The company is also exposed to credit risk from third parties, including customers, counterparties and clearing agents.
Final Take on CBOE
Cboe Global’s growth strategy of expanding its product line across asset classes, broadening geographic reach, diversifying the business mix with recurring revenues and leveraging technology reflects its operational expertise.
Its wealth distribution remains impressive. CBOE increased dividends for 13 straight years and has $644.5 million left under its current share repurchase authorization. Its discounted valuation also raises hope.
Thus, it is better to adopt a wait-and-see approach for this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intercontinental Exchange Inc. (ICE) : Free Stock Analysis Report
Cboe Global Markets, Inc. (CBOE) : Free Stock Analysis Report
OTC Markets Group Inc. (OTCM) : Free Stock Analysis Report
S&P Global Inc. (SPGI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

CBOE Outperforms Industry, Trades at a Discount: How to Play the Stock

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intercontinental Exchange Inc (Symbol: ICE), where a total of 14,258 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 52.9% of ICE's average daily trading volume over the past month of 2.7 million shares. Especially high volume was seen for the $140 strike call option expiring June 20, 2025, with 5,800 contracts trading so far today, representing approximately 580,000 underlying shares of ICE. Below is a chart showing ICE's trailing twelve month trading history, with the $140 strike highlighted in orange:
Health Catalyst Inc (Symbol: HCAT) saw options trading volume of 2,911 contracts, representing approximately 291,100 underlying shares or approximately 52.1% of HCAT's average daily trading volume over the past month, of 559,065 shares. Especially high volume was seen for the $5 strike call option expiring January 16, 2026, with 2,337 contracts trading so far today, representing approximately 233,700 underlying shares of HCAT. Below is a chart showing HCAT's trailing twelve month trading history, with the $5 strike highlighted in orange:
And Crown Castle Inc (Symbol: CCI) saw options trading volume of 14,487 contracts, representing approximately 1.4 million underlying shares or approximately 51.6% of CCI's average daily trading volume over the past month, of 2.8 million shares. Especially high volume was seen for the $90 strike call option expiring June 20, 2025, with 5,320 contracts trading so far today, representing approximately 532,000 underlying shares of CCI. Below is a chart showing CCI's trailing twelve month trading history, with the $90 strike highlighted in orange:
For the various different available expirations for ICE options, HCAT options, or CCI options, visit StockOptionsChannel.com.
Also see:
ETFs Holding IBN
SCHH YTD Return
Institutional Holders of ID
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Periodand min./max. price, $	Price change, %		Volatility, %		Volume, $
Periodand min./max. price, $	ICE	Industry	ICE	Industry	Volume, $
Yesterday 180.6 - 181.4	0.15	7.40	11.58	1.02	7.87M
Week 179.0 - 182.7	0.44	7.95	1.84	3.74	1.07B
Month 177.5 - 184.0	1.21	8.05	3.54	8.05	4.52B
3 Months 153.1 - 184.0	15.09	7.81	6.20	16.87	16.83B
6 Months 147.2 - 184.0	21.00	8.42	11.80	25.79	34.58B
Year 142.3 - 184.0	21.95	21.56	18.08	35.89	61.74B
3 years 88.6 - 184.0	84.33	125.84	33.61	65.34	133.47B
5 years 88.6 - 184.0	92.15	88.34	45.76	95.88	220.61B
All time 6.3 - 167.6	2,018.36	153.44	—	—	203.16B

Intercontinental Exchange Inc.

Price and volatility history

Risk ratios